Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II of Lenvatinib Plus Programmed Cell Death 1 Antibody for Advanced Hepatocellular Carcinoma

NCT03746249 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT03746249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03746249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II of Lenvatinib Plus Programmed Cell Death 1 Antibody for Advanced Hepatocellular Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Withdrawn
Start date
December 17, 2018
Completion date
December 1, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma